Abstract: Peptides derived from NKp44 protein, chimeric peptides, nucleotides encoding same and pharmaceutical compositions comprising same, are provided. Further, methods of extending the biological half-life of a protein of interest are provided.

Abstract: The present invention provides a monoclonal antibody or an antigen-binding portion thereof having increased binding affinity to cytoplasmic PCNA and blocks its interaction with NKp44. The present invention further provides use of the antibody or an antigen-binding portion thereof in the treatment of diseases associated with elevated expression of NKp44, such as cancer.

Abstract: A method of altering the composition of the microbiome of an adult ruminant is disclosed. The method comprises administering to the ruminant when it is the newborn stage of life, a composition which alters the amount of bacteria of the Akkermansia genus in the microbiome of the newborn ruminant, thereby altering the composition of the microbiome of the adult ruminant.

Abstract: The present invention relates to peptides comprising analogues of VDAC1-derived peptides having improved pharmacokinetic characteristics compared to the native parent peptides, which are effective in impairing cell energy production, in inducing apoptosis and cell death, particularly of cancerous cells, in eliminating cancer stem cells and in reducing symptoms associated with fat accumulation in liver cells particularly with nonalcoholic fatty liver disease (NAFLD) and symptoms associated thereto.

Abstract: A method of selecting a ruminating animal having a desirable, hereditable trait is disclosed. The method comprises analyzing in the microbiome of the animal for an amount of a hereditable microorganism which is associated with the hereditable trait, wherein the amount of the hereditable microorganism is indicative as to whether the animal has a desirable hereditable trait.

Abstract: The present invention relates to compositions and methods for treating cancer, particularly to agents that inhibit the expression and/or activity of the protein second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI (SMAC/Diablo). The inhibiting agents include RNA interference molecules silencing the expression of SMAC/Diablo and peptides modulating its interactions within the cell nucleus and mitochondria. The methods and agents of the present invention are useful in treating cancers associated with overexpression of SMAC/Diablo.

Abstract: Provided herein piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction. Also provided methods of treatment of diseases associated with said processes, e.g. Alzheimer's and Parkinson's diseases.

Abstract: The present invention relates to biomarkers of lung cancer, particularly to markers that enable distinguishing between subtypes of non-small cell lung cancer (NSCLC), particularly between adenocarcinoma (AC) and squamous cell carcinoma (SCC). In particular, the present invention relates to means and methods for diagnosing, assessing the level of severity and selecting methods of treating NSCLC.

Abstract: A method of culturing an aquaculture of an aquatic animal species of interest is disclosed. The method comprises inoculating the aquaculture with bacteria of at least one genera selected from the group consisting of Pseudomonas, Limnohabitans, Janthinobacterium, Stenotrophomonas, Aeromonas, Acinetobacter and Morganella, wherein the bacteria are provided in an amount sufficient to increase the survival and/or weight of the aquatic animal, thereby culturing the aquaculture of the aquatic animal species.

Abstract: The present invention provides novel biomarkers of chronic lymphocytic leukemia (CLL). Specifically, the present invention provides methods and kits for diagnosing, assessing the level of severity, and treating of CLL.

Abstract: The present invention discloses the use of RNA inhibitory molecules, particularly siRNA molecules silencing the expression of Voltage-Dependent Ion Chanel-1 (VDAC1) for the induction of cancer stem cell differentiation and reduction of TAMS abundance and tumor angiogenesis, thereby preventing tumor invention and recurrence.

Abstract: Mutant M-CSF protein, comprising ?v?3 integrin binding motif and pharmaceutical compositions comprising same, are provided. Further, use of the composition for the treatment and or prevention of diseases associated with increased bone resorption are provided.

Abstract: Provided are RNA inhibitory molecules, particularly siRNA molecules silencing the expression of Voltage-Dependent Ion Chanel-1 (VDAC1) for the induction of cancer stem cell differentiation and reduction of TAMs abundance and tumor angiogenesis, thereby preventing tumor invention and recurrence.

Abstract: Peptides derived from NKp44 protein, chimeric peptides, nucleotides encoding same and pharmaceutical compositions comprising same, are provided. Further, methods of extending the biological half-life of a protein of interest are provided.

Abstract: Mutant M-CSF protein, comprising ?v?3 integrin binding motif and pharmaceutical compositions comprising same, are provided. Further, use of the composition for the treatment and or prevention of diseases associated with increased bone resorption are provided.

Abstract: The present invention provides anti-microbial compositions comprising a hydroxycinnamic acid and related conjugates, analogues and derivatives, and methods of use thereof for enhancing production of anti-microbial agents in bacteria as well as for protecting plants from microbial infection.

Abstract: The present invention relates to use of small organic compounds interacting with the Voltage-Dependent Anion Channel (VDAC) for the treatment of diseases associated with central nervous system (CNS) disorders, including psychotic disorders, mood disorders, neurodegenerative diseases. In particular the present invention relates to the use of substituted piperazine- and piperidine-derivatives and pharmaceutical compositions comprising same for the treatment of psychotic disorders including schizophrenia, mood disorders, and neurodegenerative diseases.

Abstract: The present invention relates to peptides comprising analogues of VDAC1-derived peptides having improved pharmacokinetic characteristics compared to the native parent peptides, which are effective in impairing cell energy production, in inducing apoptosis and cell death, particularly of cancerous cells, in eliminating cancer stem cells and in reducing symptoms associated with fat accumulation in liver cells particularly with nonalcoholic fatty liver disease (NAFLD) and symptoms associated thereto.

Abstract: A method of selecting a ruminating animal having a desirable, hereditable trait is disclosed. The method comprises analyzing in the microbiome of the animal for an amount of a hereditable microorganism which is associated with the hereditable trait, wherein the amount of the hereditable microorganism is indicative as to whether the animal has a desirable hereditable trait.

Abstract: Described herein are isolated regulatory peptides of protein kinase C, chimeric peptides thereof, and their variants. Use of the described peptides, in compositions and methods for treatment of cellular proliferation pathologies is also described.